ArticleJournal of nanobiotechnology2026
Dual-functional cationic hydrogel engineered for simultaneous prevention of postoperative tumor recurrence and wound infection.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Postoperative recurrence and infection continue to pose major challenges after tumor resection. To address these, we developed a multifunctional nanocomposite hydrogel, designated as Gel@CAR-M@Mn@ELE. It is constructed by encapsulating CAR-M@Mn@ELE and immunomodulatory/antibacterial Dendrobium officinale polysaccharide (DOP) within a quaternary ammonium-modified gelatin methacryloyl hydrogel matrix. The CAR-M@Mn@ELE not only loads elemene (ELE) into porous Mn nanozymes (Mn NPs) but is also coated with EpCAM-targeting chimeric antigen receptor-engineered 293T cell membranes (CAR-M). Notably, through multiple modifications, the catalytic activity of Mn NPs has been preserved. In vitro studies demonstrated that CAR-M@Mn@ELE selectively targeted and killed 4T1 cancer cells (EpCAM
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.